Boehringer Survodutide SYNCHRONIZE-1 Pre-Specified Body Composition: 34% Visceral Fat and 63% Liver Fat Reduction, Lean Mass Preserved
Boehringer Ingelheim and Zealand Pharma presented a pre-specified body-composition analysis of SYNCHRONIZE-1 at ADA's Monday session: survodutide produced up to 34% relative reduction in visceral fat and 63.1% reduction in liver fat from baseline at 76 weeks, while limiting lean-mass loss. The company also disclosed SYNCHRONIZE-MASLD results: 6 of 10 patients with MASLD reached liver-fat normalization at 48 weeks. The body-composition story is Boehringer's response to a 16.6% headline weight number that analysts had called less competitive than Lilly's.